Finally had a chance to listen to the presentation, and all I can say, very excited. Harvey said nothing to suggest any problems with 113 or Iclusig. I am really looking forward to hearing about 113 MTD at ASCO and Iclusig's other indicatinons at ASH at the end of the year. It appeared pretty clear from listening to Harvey that 300mg is NOT the MTD for 113, and that he feels confident in it's ability to handle EGFR. Patience is king here right now. Thinking about upcoming events and progression of the current trials, two years sounds golden.
News 
Market Data 
Discover 
AI
